| Autor: |
Coşkun, Ayşenur, Gökahmetoğlu, Selma, Özmen, Pelin, Karakükcü, Özmen, Kaynar, Leylagül, Kuşkucu, Mert Ahmet, Midilli, Kenan |
| Předmět: |
|
| Zdroj: |
Journal of Basic & Clinical Health Sciences; Jan2023, Vol. 7 Issue 1, p270-276, 7p |
| Abstrakt: |
Purpose: Cytomegalovirus (CMV) causes asymptomatic disease in individuals with a normal immune system; and leads to serious complications in immunocompromised individuals and fetuses. In CMV, gB is the most studied glycoprotein in terms of genotyping. Up to now, four different gB genotypes (gB 1-4) of CMV have been identified. In this study, it was aimed to determine the genotypes of CMV strains obtained from patients with immune deficiency. Material and Methods: Twenty children and 29 adults, 49 patients who were followed in the Department of Adult Hematology and Pediatric Hematology were included in the study. DNA isolation was performed from samples with CMV DNA levels of 1000 IU / ml and above, and 474 bp region from the gB region of the virus was amplified by nested PCR. This region was sequenced by the Sanger (ABI 3500 Prism) sequencing. Next generation sequencing (NGS) method was applied to the samples whose CMV genotype could not be determined by Sanger sequencing. Results: Distribution of CMV genotypes of patients determined by Sanger sequencing; while it was determined as 18/49 (36.7%) type 1, 5/49 (10.2%) type 2, 5/49 (10.2%) type 3 and 1/49 (2%) type 4; 14/49 (28.5%) of them were found as mixed genotypes. CMV genotype could not be determined in 6 patients by Sanger sequencing and CMV genotype of these 6 patients was found as mixed genoype by NGS. A mixed genotype was detected in 20 (40.9%) of 49 patients, in total by Sanger sequencing and NGS. Conclusion: Mixed genotypes were detected most commonly in our study, and it is recommended that genotypes that cannot be determined by Sanger sequencing should be studied with NGS. It can be thought that genotype determination will be a determining factor in the treatment of CMV disease and in prospective vaccine development studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
